Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Nitrates or nitrites or nitric acid or nitrogen oxides
Reexamination Certificate
2006-04-14
2010-06-29
Arnold, Ernst V (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Nitrates or nitrites or nitric acid or nitrogen oxides
Reexamination Certificate
active
07744928
ABSTRACT:
Methods and compositions for inducing apoptosis of cells, such as macrophages, at a lesioned site of a body vessel are disclosed herein. Nitric oxide can be directly or indirectly delivered to a treatment site to increase macrophage apoptosis. Delivery can include site specific delivery of nitric oxide gas, nitric oxide in aqueous solution or a substance(s) which releases nitric oxide or causes nitric oxide to be generated from an endogenous source. Delivery can be achieved by a delivery system such as a catheter assembly, stent or other suitable device.
REFERENCES:
patent: 5648101 (1997-07-01), Tawashi
patent: 5676963 (1997-10-01), Keefer et al.
patent: 5861168 (1999-01-01), Cooke et al.
patent: 5935135 (1999-08-01), Bramfitt et al.
patent: 6153186 (2000-11-01), Stamler et al.
patent: 6156053 (2000-12-01), Gandhi et al.
patent: 6356536 (2002-03-01), Repke
patent: 6425881 (2002-07-01), Kaesemeyer
patent: 6569688 (2003-05-01), Sivan et al.
patent: 6656506 (2003-12-01), Wu et al.
patent: 7022334 (2006-04-01), Ding
patent: 2002/0082221 (2002-06-01), Herrmann et al.
patent: 2002/0094985 (2002-07-01), Herrmann et al.
patent: 2005/0145258 (2005-07-01), Dong
patent: 2005/0249777 (2005-11-01), Michal et al.
patent: 1 393 723 (2004-03-01), None
patent: WO 00/62614 (2000-10-01), None
patent: WO 03/017989 (2003-03-01), None
patent: WO 2005/070008 (2005-08-01), None
patent: WO 2007/097875 (2007-08-01), None
Schwarzacher et al. (Circulation 1997, 95, 1863-1869).
Baggio, R., et al., “Biochemical and Functional Profile of a Newly Developed Potent and Isozyme-Selective Arginase Inhibtor,”Journal of Pharmacology and Experimental Therapeutic, vol. 290, No. 3 (1999) pp. 1409-1416.
Berkowitz, D.E., et al., “Arginase Reciprocally Regulates Nitric Oxide Synthase Activity and Contributes to Endothelial Dysfunction in Aging Blood Vessels,”Circulation, vol. 108 (2003) pp. 2000-2006.
Boyle, J.J., et al., “Human Macrophage-Induced Vascular Smooth Muscle Cell Apoptosis Requires NO Enhancement of Fas/Fas-L Interactions,”Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22 (2002) pp. 1624-1630.
Gotoh, T. and M. Mori, “Arginase II Downregulates Nitric Oxide (NO) Production and Prevents NO-Mediated Apoptosis in Murine Macrophage-derived RAW 264.7 Cells,”Journal of Cell Biology, vol. 144, No. 3 (Feb. 8, 1999) pp. 427-434.
Li, H., et al., “Activities of arginase I and II are limiting for endothelial cell proliferation,”Am J Physiol Regulatory Integrative Comp Physiol, vol. 282 (2002) pp. R64-R69.
Tuomisto, T.T., et al., “Gene Expression in Macrophage-Rich Inflammatory Cell Infiltrates in Human Atherosclerotic Lesions as Studied by Laser Microdissection and DNA Array,”Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23 (2003) pp. 2235-2240.
Wang, B.Y., et al., “Regression of Atherosclerosis: Role of Nitric Oxide and Apoptosis,”Circulation, vol. 99 (1999) pp. 1236-1241.
Wei, L.H., et al., “Elevated arginase I expression in rat aortic smooth muscle cells increases cell proliferation,”Proceedings of the National Academy of Sciences, vol. 98 (2001) pp. 9260-9264.
Niebauer, J. et al., “Local L-arginine delivery after balloon angioplasty reduces monocyte binding and induces apoptosis”Circulation, vol. 100, 1999, pp. 1830-1835.
PCT Search Report and Written Opinion for PCT/US2007/008934, mailed Oct. 30, 2007, 15 pages.
Pulfer, S. K. et al., “Incorporation of Nitric Oxide-Releasing Crosslinked Polyethyleneimine Microspheres into Vascular Grafts”,Journal of Biomedical Materials Research, vol. 37, No. 2, Nov. 1997, pp. 182-189.
Consigny Paul
Ludwig Florian Niklas
Pacetti Stephen
Advanced Cardiovascular Systems Inc.
Arnold Ernst V
Blakely , Sokoloff, Taylor & Zafman LLP
LandOfFree
Methods and compositions for treatment of lesioned sites of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment of lesioned sites of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment of lesioned sites of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169227